Allogene Therapeutics, Inc. (ALLO) stock analysis
Close on Nov 11, 2026Market cap $310.98MP/E –Yield 0.00%
StockData Score
Prices as of Nov 11, 2026How the score works
Weak3 of 30 checks passed
Allogene Therapeutics passes 3 of the 30 checks behind our score; 21 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 1/6
- Growth
- 0/6
- Past performance
- 1/6
- Financial health
- 1/6
- Dividend
- 0/6
What stands out
P/B below the industry
Allogene Therapeutics's price-to-book of 0.79 is below the Drugs median of 2.29.
Return on equity above the industry
Allogene Therapeutics's return on equity of -49.3% is above the Drugs median of -58.8%.
Short-term assets cover short-term debts
Current assets are 7.79 times current liabilities.
What to watch
Return on equity under 15%
Return on equity was -49.3% over the last twelve months and averaged -45.1% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was -718%, below the 10% that usually covers the cost of capital.
Interest not well covered
Operating income covers interest expense -142.5 times; we look for at least 5.
Elevated bankruptcy risk
The Altman Z-score is -4.92; above 3 is the safe zone and below 1.8 the distress zone.
Valuation1/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B below the industry
Allogene Therapeutics's price-to-book of 0.79 is below the Drugs median of 2.29.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth0/6
Revenue growth over 3 years
Needs three years of positive revenue.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growth against the industry
Needs revenue for this year and last.
Guidance lowered
Allogene Therapeutics lowered its 2026 non-cash stock-based compensation expense outlook on May 13, 2026.
Gross margin trend
This company does not report gross profit.
Past performance1/6
Return on equity under 15%
Return on equity was -49.3% over the last twelve months and averaged -45.1% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was -718%, below the 10% that usually covers the cost of capital.
Return on equity above the industry
Allogene Therapeutics's return on equity of -49.3% is above the Drugs median of -58.8%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin against the industry
Needs revenue and net income.
Financial health1/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt coverage
Needs operating cash flow.
Interest not well covered
Operating income covers interest expense -142.5 times; we look for at least 5.
Short-term assets cover short-term debts
Current assets are 7.79 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is -4.92; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Allogene Therapeutics has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Allogene Therapeutics. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/B at month end
- Own 5-year median 1.2
- Drugs median 2.3
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Medium risk
- Average value traded per day
- $11.06M
- Value traded per 1% price move
- $3.44M
Downside
High risk
- Typical loss in a bad month
- 26.3%
- Volatility (annualized)
- 83%
- Sharpe ratio, 1 year
- -0.34
- Beta to the S&P 500 (5Y)
- 1.62
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2017 to 2025
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -38.5% | -53.4% | |
| Return on assets | – | -32.5% | -39.6% | |
| Current ratio | – | 8.96 | 7.93 | |
| Interest coverage | – | – | -194.7× | |
| Capex to revenue | – | – | – | |
| Diluted shares | – | 120M | 221M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Allogene Therapeutics generated $992.61M from operations and spent $29.23M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -1170863.6% | 0.00× | 1.28× | -55.1% |
| FY2023 | -344489.5% | 0.00× | 1.24× | -55.5% |
| FY2022 | -218214.1% | 0.00× | 1.18× | -42.8% |
| FY2021 | -159.6% | 0.10× | 1.18× | -18.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero-$190.89M
- Cash generatingOperating cash flow above zero-$149.25M
- Return on assets improvedROA up on the prior year-40.1% → -34.8%
- Earnings backed by cashOperating cash flow above net income-$149.25M vs -$190.89M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.54 → 7.93
- No dilutionShare count did not rise195M → 221M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00
See a number that looks wrong?